Phase 2 Interstitial Lung Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign and date a consent form agreeing to take part in the study
• People who are willing to follow all study procedures and are available for the full length of the study
• People who are currently being treated for IPF (idiopathic pulmonary fibrosis) by a lung specialist
• People who are over 50 years of age
• People who have a confirmed diagnosis of IPF according to the latest international expert guidelines for diagnosing this condition
• People who have had a special detailed lung scan (called an HRCT) done in the 6 months before joining the study as part of their regular care
• People whose lung scan shows a specific scarring pattern called "definite or probable UIP," or who have had a surgical lung tissue sample taken that shows the same pattern
• People whose lung scan shows more scarring than air-trapping (emphysema)
• People who are able to swallow tablets and are willing to take the study treatment as directed
• People who are able to use video calling software (CS-Link, Zoom, or Doximity) for virtual study appointments
• People who are able to complete breathing tests and a 6-minute walking test every 12 weeks as part of their regular care, ordered by their lung specialist
• People who are able to complete lung scans at the start of the study and again at 24 weeks, as part of their regular care
• People who are willing to have blood drawn at home and travel to a local Quest Diagnostics lab when needed
• People who currently live in one of the following US states: California, Arizona, Georgia, Louisiana, Minnesota, or Oregon

Who may not be able to join:

• People whose breathing test results fall below certain levels of lung function, indicating very severely reduced lung capacity (confirm with trial site)
• People who show signs of a different lung condition caused by an underlying cause such as an autoimmune or connective tissue disease, past exposures, certain medications, or workplace substances
• People who have other lung conditions such as asthma, tuberculosis, sarcoidosis, or ongoing lung infections
• People who have had an acute illness or fever that has not fully cleared up at least 14 days before their screening or first study visit
• People who have used tobacco products in the last 3 months, or who are not willing to avoid tobacco for the full duration of the study
• People who have taken part in another clinical trial involving an experimental drug in the 30 days before screening
• People who have any condition that, in the opinion of the study investigators, would make it hard to interpret the study results
• People who have a serious illness that is likely to result in death within the next year
• People who are unable to produce consistent, reliable breathing test results
• People who are likely to need a lung transplant within the first 12 weeks of the study
• People who are using other non-standard treatments for IPF, including certain medications such as endothelin receptor antagonists, interferon gamma-1b, or N-acetylcysteine
• People who started taking pirfenidone or nintedanib (standard IPF medications) less than 60 days before screening
• People who are currently taking, or have taken within the past 60 days, certain medications that suppress the immune system or target inflammation
• People who regularly take prednisone (a steroid) at a dose greater than 10 mg per day
• People who regularly take medications known to interact significantly with zinc supplements (confirm with trial site for specific medications)
• People who have uncontrolled fluid build-up around the lungs, heart, or abdomen that needs to be drained once a month or more
• People who have had a serious heart or cardiovascular event (such as a heart attack or stroke) within the 3 months before starting the study, or who have an unstable heart rhythm or unstable chest pain
• People who have had a major surgery (not for diagnosis) within 4 weeks before starting the study, or who expect to need major surgery during the study
• People who have had an active cancer diagnosis in the last 5 years (with some exceptions such as certain early-stage or skin cancers — confirm with trial site)
• People who have previously had a bone marrow or organ transplant
• People with any other serious medical condition, abnormal test result, or physical finding that could make it unsafe to take an experimental treatment or make it difficult to interpret the study results

Important: Always verify eligibility with the trial site directly before applying.